Get our introductory offer at only
*$0.99/month for first 3 months
$29.90/month for the next 9 months
FOR almost four years, Bristol-Myers Squibb Co investors have profited handsomely thanks to the company's sharp focus on cancer. On Friday, they felt the other side of that concentrated bet.
The drop in the shares on Friday - the worst in more than 16 years - had as much